Pharmaceutical Commerce

Featured Content

Pharmaceutical Commerce - December 2023

Click here to read the articles and download the PDF

The Business Case for RWE

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

Who Moved My Prescription?

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Transforming the Patient Hub into a Hub of Patient Centricity

Methods that pharma companies can use to make the hub more personalized and experiential.

How Drug Shortages Affect Drug Pricing in China

December 06, 2023

A study explores how supply and demand impact the value of medication.

Transforming the Patient Hub into a Hub of Patient Centricity

December 06, 2023

Methods that pharma companies can use to make the hub more personalized and experiential.

Fabhalta Gains FDA Approval for Treatment of Paroxysmal Nocturnal Hemoglobinuria

December 06, 2023

Novartis anticipates Fabhalta to be available in the United States in December for the treatment of paroxysmal nocturnal hemoglobinuria.

Navigating the Biosimilars Marketplace

December 06, 2023

How to provide effective brand engagement in this rocky yet emerging landscape.

An Outlook on Data-Powered Patient Support

December 06, 2023

Matt Wolf, president of biopharma services, Cencora, discusses the importance of partnership in helping to combat prescription drug abandonment and non-adherence.

Prescribing Resilience: Third-Party Risks and Pharma

December 05, 2023

What stands between pharma and other industries when it comes to remaining vigilant?

Obesity Treatment Zepbound Now Available in United States

December 05, 2023

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Investigational Treatment for High-Risk Bladder Cancer Awarded FDA Breakthrough Designation

December 05, 2023

Johnson & Johnson’s TAR-200 has a novel targeted releasing system that allows for a controlled release of gemcitabine in patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

Opdivo Combination Granted FDA Priority Review for Unresectable, Metastatic Urothelial Carcinoma

December 05, 2023

Opdivo (nivolumab) plus cisplatin-based chemotherapy shows improved survival benefits in the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

Generative Artificial Intelligence Could Transform Healthcare if Challenges Are Addressed

December 04, 2023

Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.